Ostatné · UTHR

United Therapeutics Corporation

542,81 1,11 (+0,20 %) aktualizované práve teraz

1 týždeň+11,8 %

1 mesiac+11,3 %

3 mesiace−0,8 %

1 rok+19,8 %

52t minimum415,34

52t maximum596,76

RSI 1460

SMA 50511,39

SMA 200525,55

Fundamenty firmy Healthcare · Drug Manufacturers - Specialty & Generic · United States

Hodnotenie 0–10, vypočítané z údajov firmy

Finančná siladlh voči vlastnému kapitálu, likvidita

Ziskovosťmarže, návratnosť kapitálu (ROE)

Rastrast tržieb a ziskov

OcenenieP/E, PEG, P/B – vyššie = lacnejšie

Orientačné skóre v štýle GuruFocus – nie je to odporúčanie.

Analytici 14 hodnotení

nákup

Najnižší cieľ: 321,00
Priemerný cieľ: 644,36
Najvyšší cieľ: 728,00
Potenciál: +18,7 %

3831

silný nákup · nákup · držať · predaj · silný predaj

Oceniť v DCF kalkulačke →

Trhová kapitalizácia ?23,3 mld. P/E ?19,4 P/E budúce ?17,9 PEG ?2,22 P/B ?3,6 EV/EBITDA ?13,7 Dividendový výnos ?– Čistá marža ?41,6 % ROE ?19,3 % Dlh / vlastný kapitál ?– Rast tržieb ?−1,9 % Rast ziskov ?+13,4 % Voľný cash flow ?557,1 mil. Tržby ?3,2 mld. Beta ?0,49 Podiel inštitúcií ?100 %

Odhad zisku na akciu (EPS)

Obdobie	Odhad	Rozpätie	Pred rokom	Rast
tento štvrťrok	6,46	4,40–7,63	7,16	−9,8 %
budúci štvrťrok	6,71	3,05–8,35	7,70	−12,8 %
tento rok	26,08	22,65–29,05	27,86	−6,4 %
budúci rok	28,79	19,07–36,10	26,08	+10,4 %

Odhad tržieb

Obdobie	Odhad	Pred rokom	Rast
tento štvrťrok	786,3 mil.	799,5 mil.	−1,7 %
budúci štvrťrok	792,8 mil.	790,2 mil.	+0,3 %
tento rok	3,1 mld.	3,2 mld.	−1,3 %
budúci rok	3,5 mld.	3,1 mld.	+10,2 %

Nákupy a predaje manažérov insider

Kto	Čo	Hodnota	Dátum
Mahon Paul AGeneral Counsel	predaj	4,7 mil.	01.10.
Mahon Paul AGeneral Counsel	uplatnenie opcií	1,2 mil.	01.10.
Rothblatt Martine AChief Executive Officer	predaj	3,9 mil.	30.09.
Rothblatt Martine AChief Executive Officer	predaj	1,1 mil.	30.09.
Rothblatt Martine AChief Executive Officer	uplatnenie opcií	1,1 mil.	30.09.
Rothblatt Martine AChief Executive Officer	predaj	4,5 mil.	29.09.
Rothblatt Martine AChief Executive Officer	uplatnenie opcií	1,1 mil.	29.09.
Rothblatt Martine AChief Executive Officer	predaj	4,6 mil.	28.09.
Rothblatt Martine AChief Executive Officer	uplatnenie opcií	1,1 mil.	28.09.
Rothblatt Martine AChief Executive Officer	predaj	4,5 mil.	25.09.
Rothblatt Martine AChief Executive Officer	uplatnenie opcií	1,1 mil.	25.09.
Rothblatt Martine AChief Executive Officer	predaj	4,7 mil.	23.09.

Predaje manažérov sú bežné (dane, diverzifikácia); nákupy z vlastných peňazí bývajú silnejší signál.

Kto vlastní akcie

Blackrock Inc.12,34 %

Avoro Capital Advisors LLC6,48 %

Vanguard Portfolio Management LLC4,48 %

Vanguard Capital Management LLC4,47 %

State Street Corporation4,43 %

Renaissance Technologies, LLC3,98 %

Wellington Management Group, LLP3,22 %

Geode Capital Management, LLC2,32 %

O firme (popis z Yahoo Finance, anglicky)

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

https://www.unither.com ↗

Názor AI

Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.

Odporúčania

K tomuto aktívu zatiaľ nemáme odporúčanie.

Predikcie

Žiadne predikcie.

Súvisiace správy

Žiadne správy so značkou UTHR.

United Therapeutics Corporation ☆